As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator”s biologic products. But scientific challenges remain due to the complexity of both the manuf
Koop dit e-boek en ontvang er nog 1 GRATIS!
Formaat PDF ● Pagina’s 444 ● ISBN 9781466579705 ● Uitgeverij CRC Press ● Gepubliceerd 2013 ● Downloadbare 6 keer ● Valuta EUR ● ID 2715426 ● Kopieerbeveiliging Adobe DRM
Vereist een DRM-compatibele e-boeklezer